Mangoceuticals’ antiviral compound MGX‑0024 achieved zero respiratory‑related mortality in three independent commercial field trials involving approximately 29,000 broiler chickens, a result that represents a dramatic improvement over the expected 50 % mortality rate (about 14,500 birds) in untreated flocks.
The trials, conducted on farms in Tamil Nadu, India, used MGX‑0024‑infused drinking water from day 14 to market age (37–48 days) without concurrent antibiotics or antivirals, and recorded no deaths attributable to respiratory pathogens.
In a controlled challenge study by Vipragen Biosciences at ICAR‑NIHSAD under BSL‑3 conditions, 60 % mortality was reduced among chicks pre‑treated with MGX‑0024 before intranasal H5N1 exposure; 2 of 7 treated chicks died versus 5 of 7 untreated controls, and surviving birds exhibited minimal viral shedding and remained seronegative for H5 antibodies at day 14.
MGX‑0024 is a GRAS‑classified formulation of polyphenols and zinc delivered through standard farm drinking‑water systems. The compound is protected by U.S. Patent No. 11,517,523 and corresponding international patents, and is not yet approved for veterinary use, so the findings are preliminary and require further validation.
Mangoceuticals, whose core business is a men’s health and wellness telemedicine platform, has reported modest revenue of $361,661 for the nine months ended September 30 2025, down from $510,626 a year earlier, and a net loss of $17.9 million versus $6.8 million. The company recently raised $2.5 million in a registered direct and private placement in December 2025 and is pursuing additional grant opportunities. The MGX‑0024 results represent a diversification effort that could open a new revenue stream, but the company’s financial health remains a concern.
"We continue to advance this program with strong interest from distributors, farms, and agencies in key markets like India. We are scaling production, refining pricing and logistics, while our partner IntraMont Technologies is actively engaging in regulatory discussions in the United States, Australia, UK, Canada, and elsewhere. This aligns well with global trends toward reduced antibiotic use and sustainable poultry production," said Jacob Cohen, CEO of Mangoceuticals. "These results represent meaningful progress. Eliminating observed respiratory‑related mortality in real‑world commercial flocks, alongside a clear prophylactic signal in a controlled H5N1 challenge, positions MGX‑0024 as a promising tool for managing endemic respiratory challenges and supporting biosecurity against avian influenza threats," added Jim Intrater, President of IntraMont Technologies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.